Martin Shkreli, the former hedge fund manager known as "Pharma Bro," defended Palantir Technologies Inc.'s valuation on Tuesday amid the company's surging stock price, projecting substantial cash flow ...
Along with the better-than-expected Q4 revenue and earnings and 2025 guidance, there was likely another catalyst for investors sending Palantir stock soaring: In Q4, U.S. commercial revenue growth was ...